Most Read Articles
01 Dec 2019
Macrolide antibiotics are derived from the Streptomycesspecies. These contain either 14-membered (erythromycin [ERM],clarithromycin [CAM], roxithromycin [RXM]), 15-membered(azithromycin [AZM]) or 16-membered (spiramycin, josamycin,midecamycin) macrocyclic lactone rings. They inhibit proteinsynthesis by reversibly binding to the 23S ribosomal RNA (rRNA)in the 50s subunit of the bacterial ribosome. Traditionally,macrolides are used as first-line agents in respiratory, skin,soft tissue, and urogenital infections, and they are also activeagainst gram-positive cocci and atypical pathogens.
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
Jairia Dela Cruz, 3 days ago
Nonsmall cell lung cancer (NSCLC) patients harbouring sensitive EGFR mutations may fare well with the third-generation tyrosine kinase inhibitor osimertinib as an upfront therapy, with the results of a network meta-analysis showing that the drug tops other currently available options in terms of progression-free survival and tolerability.
01 Dec 2019
Pneumonia is a common infection– affecting around 3,200 people inSingapore in 2016 – making it the thirdmost common cause of hospitalisation inthe country. Its common complications,especially with delayed or inappropriatetreatment, include bacteraemia andseptic shock, lung abscesses, pleuraleffusions, empyema, pleurisy, respiratoryfailure and renal failure.

30-day readmission predicts mortality in hospitalized CDI patients with cirrhosis

01 Sep 2019

A third of Clostridium difficile infection (CDI) patients with cirrhosis have been readmitted in a span of 30 days primarily due to recurrent CDI, a recent study has found. In addition, there is a high rate of mortality linked to CDI in patients with cirrhosis, in which a poor prognosis is predicted by decompensation and 30-day readmission.

A total of 12,274 out of 366,283 (3.4 percent) patients hospitalized with CDI had cirrhosis. Of these, 7,741 (63.1 percent) were decompensated. Among CDI patients, those with vs without cirrhosis had higher 30-day readmission rates (33 percent vs 24 percent), index admission mortality (5 percent vs 2.5 percent) and calendar-year mortality (9 percent vs 4 percent).

The most common reasons for readmission were recurrent CDI (46 percent) and cirrhosis-related complications (34.6 percent). Patients with decompensated cirrhosis had a greater risk of readmission within 30 days than those with compensated cirrhosis (odds ratio [OR], 1.19, 95 percent CI, 1.03–1.36).

In multivariable analyses, index colectomy (OR, 6.50, 1.61–26.24) and decompensation (OR, 3.61, 2.49–5.23) predicted index admission mortality among patients with cirrhosis. Thirty-day readmission (OR, 3.71, 2.95–4.67) and decompensated cirrhosis (OR, 1.49, 1.17–1.89) were also independent predictors of calendar-year mortality.

“Reducing [recurrent] CDI-related readmissions may potentially improve these outcomes,” the investigators said.

This study used the Nationwide Readmission Database (2011–2014) to identify hospitalized patients with CDI and differentiate them according to the presence of cirrhosis. Baseline characteristics, surgical rates and outcomes were obtained. The primary outcomes were readmission and mortality rates.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
01 Dec 2019
Macrolide antibiotics are derived from the Streptomycesspecies. These contain either 14-membered (erythromycin [ERM],clarithromycin [CAM], roxithromycin [RXM]), 15-membered(azithromycin [AZM]) or 16-membered (spiramycin, josamycin,midecamycin) macrocyclic lactone rings. They inhibit proteinsynthesis by reversibly binding to the 23S ribosomal RNA (rRNA)in the 50s subunit of the bacterial ribosome. Traditionally,macrolides are used as first-line agents in respiratory, skin,soft tissue, and urogenital infections, and they are also activeagainst gram-positive cocci and atypical pathogens.
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
Jairia Dela Cruz, 3 days ago
Nonsmall cell lung cancer (NSCLC) patients harbouring sensitive EGFR mutations may fare well with the third-generation tyrosine kinase inhibitor osimertinib as an upfront therapy, with the results of a network meta-analysis showing that the drug tops other currently available options in terms of progression-free survival and tolerability.
01 Dec 2019
Pneumonia is a common infection– affecting around 3,200 people inSingapore in 2016 – making it the thirdmost common cause of hospitalisation inthe country. Its common complications,especially with delayed or inappropriatetreatment, include bacteraemia andseptic shock, lung abscesses, pleuraleffusions, empyema, pleurisy, respiratoryfailure and renal failure.